Skip to main content
Signal8
Launch Terminal

Ceribell, Inc. (CBLL)

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.

Sector: Electromedical & Electrotherapeutic Apparatus

Industry: Medical - Devices

CeriBell, Inc. logo

CeriBell, Inc.

NASDAQ:CBLLHealthcare
-4.46%$26.58
AH$26.58+0.00%vs close
Mkt Cap$1.02B
Float23.08M
O/S38.38M
Vol
$ Vol
RVOL
Inst Own80.1%
SI9.3%
Earnings
Dilution
CeriBell, Inc. logoNASDAQ:CBLL$26.58-4.46%
Pipeline4 lead-sponsored trials·3 active1 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Observational
    Completed

    Does Use of Rapid Response EEG Impact Clinical Decision Making

    Ceribell Rapid Response EEG, Survey

    Nonconvulsive Status Epilepticus, Seizures

    Enrollment
    164
    Start
    Apr 2018
    Primary Completion
    Apr 2019
    Completion
    Jul 2019
    NCT03534258
  • Observational
    Recruiting

    Ceribell Delirium Data Collection Study

    Electroencephalogram (EEG) Test

    Delirium

    Enrollment
    200
    Start
    Nov 2021
    Primary Completion
    Dec 2025est.
    Completion
    Apr 2026est.
    NCT04962815
  • Not applicable
    Recruiting

    Ceribell Delirium Monitor Outcomes Pilot Study

    Ceribell Delirium Monitoring System

    Delirium in the Intensive Care Unit

    Enrollment
    100
    Start
    Mar 2026
    Primary Completion
    Oct 2026est.
    Completion
    Dec 2026est.
    NCT07449416
  • Observational
    Recruiting

    EEG Abnormalities in Adult ICU Patients With High Risk of Delirium

    Ceribell EEG System

    Delirium in the Intensive Care Unit

    Enrollment
    100
    Start
    Apr 2026
    Primary Completion
    Dec 2026est.
    Completion
    Sep 2027est.
    NCT07485244
Search ClinicalTrials.gov for “Ceribell”